Addex and the SIB Swiss Institute of Bioinformatics Receive Innosuisse Grant to Repurpose Potent Dopamine Antagonist Using Co...
August 27 2020 - 1:00AM
ADX10061
Previously Demonstrated Favorable Safety and Tolerability in
Clinical Studies
Geneva, Switzerland, August 27,
2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a
clinical-stage pharmaceutical company pioneering allosteric
modulation-based drug discovery and development, and the SIB Swiss
Institute of Bioinformatics (SIB) today announced that they have
been awarded a CHF600K Innosuisse grant to apply computational
approaches developed by SIB to identify new therapeutic indications
for ADX10061, a potent and selective dopamine D1 receptor
antagonist. Dopamine is a major neurotransmitter in the central
nervous system and D1 receptors are believed to play an important
role in the control of diverse aspects of brain function, including
cognition, motivation, motricity, sleep, and memory.
“The diversity of D1-dopaminergic systems in the
body and availability of promising clinical and pre-clinical study
data is a strong basis to successfully apply advanced computational
approaches, such as those developed by SIB, to identify new
therapeutic opportunities for ADX10061,” said Robert Lütjens, PhD,
Head of Discovery Biology at Addex. “We believe SIB’s proprietary
approaches, including artificial intelligence, deep learning
techniques and molecular modelling have the potential to generate
testable hypotheses for new therapeutic effects of ADX10061.”
“The Addex molecule, ADX10061, provides a
perfect opportunity to deploy the advanced computational
technologies developed at the SIB to explore further its biological
properties and discover additional potential therapeutic
indications,” said Christine Durinx, PhD, SIB Executive Director.
“Our multidisciplinary team of data scientists are excited to have
the opportunity to work with Addex on this Innosuisse funded
project.”
“This Innosuisse funded SIB collaboration is
another example of our strategy to access technologies through
collaborative approaches to advance our portfolio for the benefit
of both patients and shareholders,” said Tim Dyer, CEO of Addex.
“We are honoured to have the opportunity to work with the SIB team
and believe they have the skills and expertise to identify new
potential therapeutic opportunities for ADX10061.”
About D1 AntagonistsThe D1
subtype is the most abundant form of dopamine receptor in the body
and is ubiquitous throughout the central nervous system. Non-human
primate studies have shown the D1 receptor to be vital in attention
and other executive processes and due to its presence in
sub-cortical regions, it may play a role in reward, addiction and
mood. Many typical and atypical antipsychotic agents act as D1
antagonists in addition to their effect on the D2 receptor. This
lack of specificity for compounds targeting the D1 recepter has
meant that no specific D1 antagonist has been approved for clinical
use.
About SIBThe SIB Swiss
Institute of Bioinformatics is an academic not-for-profit
organization whose mission is to lead and coordinate the field of
bioinformatics in Switzerland. Its data science experts join forces
to advance biological and medical research and enhance health. SIB
(i) provides the national and international life science community
with a state-of-the-art bioinformatics infrastructure, including
services, resources, expertise; and (ii) federates world-class
researchers and delivers training in bioinformatics. The institute
includes some 80 world-class research and service groups including
800 scientists in the fields of genomics, proteomics, evolution and
phylogeny, systems biology, structural biology, text mining and
machine learning and personalized health.
About Addex Therapeutics
Addex Therapeutics is a clinical-stage
pharmaceutical company focused on the development and
commercialization of an emerging class of novel orally available
small molecule drugs known as allosteric modulators for
neurological disorders. Allosteric modulators offer several
potential advantages over conventional non-allosteric molecules and
may offer an improved therapeutic approach to conventional
"orthosteric" small molecule or biological drugs. Addex's
allosteric modulator drug discovery platform targets receptors and
other proteins that are recognized as essential for therapeutic
intervention. Addex's lead drug candidate, dipraglurant (mGlu5
negative allosteric modulator or NAM), is scheduled to enter a
pivotal registration clinical trial for Parkinson’s disease
levodopa induced dyskinesia (PD-LID). In parallel, dipraglurant's
therapeutic use in dystonia is being investigated in preclinical
models. Addex's second clinical program ADX71149 (mGlu2 positive
allosteric modulator or PAM), developed in collaboration with our
partner Janssen Pharmaceuticals, Inc., is scheduled to enter a
Phase 2a proof of concept clinical study for the treatment of
epilepsy. In addition, Addex’s GABAB PAM program has been
licensed to Indivior PLC for the treatment of addiction.
Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM
for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM
for Parkinson’s disease and mGlu3 PAM for neurodegenerative
disorders.
Press Contacts:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15
55Email: PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
Forward Looking
StatementsCertain statements made in this announcement are
forward-looking statements including with respect to the creation
of a trading market for ADSs representing the Company's shares
in the United States. These forward-looking statements are not
historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company's control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements. The Company cautions securityholders
and prospective securityholders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Apr 2023 to Apr 2024